Screening, domestication and identification of intestinal uric acid degrading bacteria in low uric acid population.
10.7507/1001-5515.202111028
- Author:
Tingting TIAN
1
;
Wujin CHEN
2
;
Meiting LIANG
1
;
MAYINA KAHAER
3
;
Rui LI
3
;
Yuping SUN
3
Author Information
1. Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China.
2. Morphological Center, Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China.
3. Department of Microbiology, Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China.
- Publication Type:Journal Article
- Keywords:
Domestication;
Low uric acid population;
Screen;
Uric acid degradation rate;
Uric acid degrading bacteria
- MeSH:
Bacteria/metabolism*;
Domestication;
Ecosystem;
Escherichia coli/genetics*;
Humans;
Hyperuricemia;
RNA, Ribosomal, 16S/metabolism*;
Uric Acid/metabolism*
- From:
Journal of Biomedical Engineering
2022;39(4):792-797
- CountryChina
- Language:Chinese
-
Abstract:
As the largest ecosystem of human body, intestinal microorganisms participate in the synthesis and metabolism of uric acid. Developing and utilizing intestinal bacteria to degrade uric acid might provide new ideas for the treatment of hyperuricemia. The fecal samples of people with low uric acid were inoculated into uric acid selective medium with the concentration of 1.5 mmol/L for preliminary screening, and the initially screened strains that may have degradation ability were domesticated by concentration gradient method, and the strains with high uric acid degradation rate were identified by 16S rRNA sequencing method. A strain of high-efficiency uric acid degrading bacteria was screened and domesticated from the feces of people with low uric acid. The degradation rate of uric acid could reach 50.2%. It was identified as Escherichia coli. The isolation and domestication of high efficient uric acid degrading strains can not only provide scientific basis for the study of the mechanism of intestinal microbial degradation of uric acid, but also reserve biological strains for the treatment of hyperuricemia and gout in the future.
